When will Roche report earnings and why does it matter for RO.SW stock?

Roche reports earnings on **29 Jan 2026**. The report matters for RO.SW stock because it will update revenue, EPS, and guidance. Investors watch diagnostics growth and Genentech investments to judge near-term valuation and price direction.

What are the main valuation metrics to watch for RO.SW stock?

Key metrics include **PE 30.38**, EPS **11.73**, price-to-book **9.74**, and EV/EBITDA around **24.33**. These show a premium valuation that earnings and guidance must justify for RO.SW stock to advance.

How does Meyka AI view RO.SW stock right now?

Meyka AI rates RO.SW **69.14** out of 100 (Grade B, HOLD). The grade balances sector comparison, growth metrics, and forecasts. It is informational and not investment advice for RO.SW stock.

What short-term price action should traders expect for RO.SW stock?

Expect event-driven volatility around the earnings release. RSI **70.92** signals overbought conditions, so traders should manage risk. Volume below the 50-day average suggests selective flows into RO.SW stock.

CH Stocks

Roche Holding AG (RO.SW) SIX after hours CHF356.60 26 Jan 2026: earnings due 29 Jan may reset outlook

ByHuzaifa Zahoor January 26, 2026January 26, 2026

RO.SW stock closed after hours at CHF 356.60 on SIX on 26 Jan 2026 as investors position ahead of Roche Holding AG’s earnings report due 29 Jan 2026. The market is watching revenue growth, EPS of 11.73, and the company’s diagnostics momentum. Volume was 13,200 versus a 50-day average of 26,118, suggesting cautious trading. This earnings spotlight will test Roche’s premium multiple and guide near-term price action for the Switzerland-listed healthcare leader.